Navigation Links
Veracyte, Inc. Announces Third Quarter 2013 Financial Results
Date:11/25/2013

amp; Metabolism and presented at the 83rd Annual Meeting of the American Thyroid Association (ATA).
  • Positive findings presented at the American Society of Cytopathology's 61st Annual Scientific Meeting suggest that the Afirma GEC, when supplemented with an additional gene set, can accurately identify medullary thyroid cancer (MTC) pre-operatively among thyroid nodule fine needle aspiration (FNA) samples that are indeterminate by cytopathology.
  • Received a New York State Department of Health clinical laboratory permit for Veracyte's CLIA laboratory facility located in Austin, Texas.
  • Completed an IPO on November 4, 2013, raising gross proceeds of $65 million.
  • Third Quarter 2013 Financial Results

  • Cash and cash equivalents as of September 30, 2013 totaled $15.4 million.
  • The company received 12,417 FNA samples during the third quarter of 2013, compared to 7,052 FNA samples during the same period in 2012, an increase of 76%. Afirma GEC tests continued to be performed at a rate of approximately 20% of FNA samples received.
  • Revenue for the third quarter of 2013 was $5.6 million, compared with revenue of $3.2 million for the comparable period in 2012.
  • Total operating expenses for the third quarter of 2013 were $11.7 million, compared with total operating expenses of $8.2 million for the comparable period in 2012. Cost of revenue was $3.1 million for the third quarter of 2013, compared with $2.0 million for the comparable period in 2012. Research and development expenses were $2.0 million for the three months ended September 30, 2013, compared to $1.7 million for the same period in 2012. Selling and marketing expenses were $3.3 million for the third quarter of 2013, compared with $2.3 million for the third quarter of 2012. General and administrative expenses were $3.2 million for the third quarter 2013, compared with $2.1 million for the same period in 2012.

  • '/>"/>
    SOURCE Veracyte
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
    2. Veracyte, Inc. Announces Pricing of Initial Public Offering
    3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
    4. Golden Meditech Announces 2013 / 2014 Interim Results
    5. iHealth Announces Results of AHA Walking Challenge
    6. Unilife Announces Results of 2013 Annual General Meeting
    7. Hanger Announces Appointment of Christopher B. Begley to Board of Directors
    8. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013
    9. Array BioPharma Announces Management Team Change
    10. Hill-Rom Holdings, Inc. Announces First Quarter 2014 Dividend
    11. Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... , 28 luglio 2014 ResMed (NYSE: ... di prodotti per la cura dei disturbi respiratori del ... ha avuto un,ingiunzione permanente in Germania contro il produttore ... proibisce la vendita di apparecchiature da indossare in testa, ... e le maschere 220. La sentenza della Corte Regionale ...
    (Date:7/28/2014)... 2014   Cardioxyl Pharmaceuticals, Inc. announced today ... CXL-1427, a novel potential treatment for acute decompensated heart ... company has now initiated dosing of hospitalized patients with ... designed to further evaluate the drug,s safety and tolerability ... Phase I clinical trial evaluated the safety and tolerability ...
    (Date:7/28/2014)... CLARA, Calif. , July 28, 2014  ProteinSimple ... assay for the Simple Western. This new assay allows users ... For the first time, Simple Western users can analyze ... The Simple Western has changed protein analysis as ... hassles of Western blot protocols - no messy gels, ...
    Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2ProteinSimple Says "Never Run a Gel Again!" 2
    ... California Cryobank (CCB), the nation,s leading ... branch in Indianapolis, IN.  In conjunction with General ... York, Cambridge, and Palo Alto as California Cryobank,s sixth ... HCLD(ABB), and John Critser, PhD., General BioTech is a ...
    ... with active moderate to severe rheumatoid arthritis (RA) inadequately ... (Humira ® ) and who were actively switched to ... at week 10, and sustained response through week 26 ... from the RESTART study were presented for the first ...
    Cached Medicine Technology:Nation's Leading Sperm Bank Opens Branch in Indianapolis, IN 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7
    (Date:7/28/2014)... St. Jude Children’s Research Hospital has ... Defense Employer Support Freedom Award from the Employer Support of ... The award is the highest honor given by the U.S. ... serve in the National Guard and Reserve. , “We deeply ... contributions to the St. Jude mission and to our country,” ...
    (Date:7/28/2014)... 2014...Mothers who live near green spaces deliver babies ... new study, "Green Spaces and Adverse Pregnancy Outcomes" ... Medicine . , A team of researchers from ... Negev (BGU), evaluated nearly 40,000 single live births ... Israel to determine the impact of green surroundings ...
    (Date:7/28/2014)... HIV research findings made possible by a test developed ... Pharmaceutical Sciences (CU School of Pharmacy), AURORA, Colo (July 28, ... in the Colorado Antiviral Pharmacology Laboratory at the CU ... HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), ... , A study presented during the AIDS 2014 ...
    (Date:7/28/2014)... Modesto, CA (PRWEB) July 28, 2014 At ... an uncomfortable situation where they’re forced to contact the authorities. ... little more difficult than it initially seems. , Not every ... a vehicle get stolen, a person get mugged, or a ... little less obvious, leading onlookers to be more passive than ...
    (Date:7/28/2014)... The report “Industrial Enzymes Market ... Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & Geography ... and segments the global industrial enzymes market with ... industrial enzymes. It also identifies driving and restraining ... analysis of trends, opportunities, burning issues, winning imperatives, ...
    Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4
    ... of a particular drug than the individual effect of both the ... where the avian bird flu is posing a serious threat across ... is a prescribed drug for seasonal flu, because it will be ... in Asia and reported in other areas mutates into a human ...
    ... have been implicated in a number of human ... pox, measles, rubella, polio, hepatitis, warts, influenza, common ... have now //,reported that a potentially life threatening ... population. ,The findings...indicate the possible presence ...
    ... Carskadon from Bradley Hospital Sleep Laboratory, Brown University has found ... to bed late. Study has found that teens are not ... they get up early in the morning resulting in a ... in the Journal American Academy of Sleep Medicine. ...
    ... US and University of Tokyo, Japan have found a faster ... a bird flu outbreak involving mutant strain of virus occurs. ... the avian virus which may be very lethal and may ... University of Wisconsin-Madison, working with Japanese colleagues from the University ...
    ... more likely to occur in patients who take high ... safety profile of non-steroidal anti-inflammatory drugs (NSAIDs). // Furthermore, ... days after starting an ibuprofen regimen. ... favorable safety profiles of all of the traditional non-selective ...
    ... of India has today assured that there was no real ... // ,The government has set up a nationwide ... the domestic poultry population and migratory birds and to constantly ... as and when required. ,"We are keeping a ...
    Cached Medicine News:Health News:Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid 2Health News:Reports of Hantavirus infection in India raise concerns 2Health News:Faster way of producing Bird flu vaccine using Reverse Genetics 2
    Triad Plus PVP-I Scrub Winged Sponges...
    Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
    The applicator is designed for a smooth delivery of the solution for surgical procedures....
    ... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
    Medicine Products: